← Leaderboards
Humam Kadara
University Of Tx Md Anderson Can Ctr
$4,695,975
Attributed
$9,391,950
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,391,950 · 5
By mechanism
R01$7,664,072 · 4
U01$1,727,878 · 1
Top collaborators
- Seyed Javad Mirhassani Moghaddam9 shared
- Paul A Scheet4 shared
- Linghua Wang4 shared
- Tina Cascone2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Seyed Javad Mirhassani Moghaddam$4,738,281
- Linghua Wang$3,415,632
- Jonathan M Kurie$24,221,061
- Christine B Peterson$1,459,247
- Lauren Elizabeth Colbert$1,808,735
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMalignant Neoplasm Of LungMouse ModelLungTumorMutationPhenotypeLung AdenocarcinomaEvolutionPrevention StrategyEarly TreatmentExhibitsMalignant NeoplasmsSmokingEventStructure Of Parenchyma Of LungImmunePathologicProgramsPreventMolecularSomatic MutationPrognosisInflammatory
Grant awards (19)
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy$670,358
R01 · FY2025 · CA
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$613,551
R01 · FY2025 · CA · contact PI
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development$435,096
U01 · FY2025 · CA · contact PI
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$393,023
R01 · FY2025 · CA · contact PI
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy$670,358
R01 · FY2024 · CA
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$593,147
R01 · FY2024 · CA · contact PI
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$532,609
R01 · FY2024 · CA · contact PI
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development$411,223
U01 · FY2024 · CA · contact PI
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$586,157
R01 · FY2023 · CA · contact PI
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$520,592
R01 · FY2023 · CA · contact PI
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development$428,656
U01 · FY2023 · CA · contact PI
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$596,247
R01 · FY2022 · CA · contact PI
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$540,668
R01 · FY2022 · CA · contact PI
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development$452,903
U01 · FY2022 · CA · contact PI
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$556,410
R01 · FY2021 · CA · contact PI
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer$336,500
R01 · FY2019 · CA · contact PI
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer$346,909
R01 · FY2018 · CA · contact PI
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer$346,909
R01 · FY2017 · CA
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer$360,634
R01 · FY2016 · CA